Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

289.90 +2.03 (+0.71%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2 3 4 5 6 7 8 9
...
47 48 Next >
What Lies In Store For Healthcare ETFs In Q3 Earnings?
The healthcare sector has performed well in recent months, driven by the booming weight-loss drug treatment segment. As such, various healthcare ETFs have benefited. 
Via Talk Markets
Topics ETFs
2 Reliable Dividend Stocks You Can Buy and Hold Forever
There are reasons beyond the dividends to invest in these stocks. 
Via The Motley Fool
Top Stock Reports For Costco, Coca-Cola & T-Mobile US
Today's Research Daily features new research reports on 16 major stocks, including Costco Wholesale Corp., The Coca-Cola Co., and T-Mobile US, Inc., as well as a micro-cap stock Preformed Line Products... 
Via Talk Markets
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised concerns over the Catalent acquisition. 
Via Benzinga
A Closer Look at Amgen's Options Market Dynamics
Via Benzinga
Navigating 14 Analyst Ratings For Amgen
Via Benzinga
Is Amgen Stock a Buy?
This biotech leader could be poised to rally higher. 
Via The Motley Fool
Looking Into Amgen's Recent Short Interest
Via Benzinga
Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade
The analyst is closely watching MariTide, a potential monthly injection to treat obesity. 
Via Investor's Business Daily
In-Depth Examination Of 11 Analyst Recommendations For Amgen
Via Benzinga
Blue Skies, New Highs Remain Disciplined And Do Not Chase Extended Ideas
It is Fall clean up time. Sell lagging and sagging companies. 
Via Talk Markets
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns. 
Via Benzinga
2 Top Dividend Stocks to Buy Hand Over Fist Right Now
Income stocks can be wise additions to your portfolio in any market environment. 
Via The Motley Fool
(AMGN) - Analyzing Amgen's Short Interest
Via Benzinga
Analyst Expectations For Amgen's Future
Via Benzinga
18 Stocks To Buy, 7 To Sell This Earnings Season: Goldman Sachs Calls It 'The Year Of The Stock Picker'
Goldman Sachs identifies 18 stocks for potential earnings upside and advises options-based strategies in a volatile market. 10% upside for S&P 500. 
Via Benzinga
Topics Stocks
Exposures US Equities
Deere, Amgen, Copart And More: CNBC's 'Final Trades'
On CNBC's "Halftime Report Final Trades," Jim Lebenthal of Cerity Partners named Deere & Company as his final trade. 
Via Benzinga
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
The Biden administration's proposed Medicare $2 Drug List Model aims to provide low-cost generic drugs for seniors and people with disabilities, with copayments capped at $2 per month for essential... 
Via Benzinga
2 Biotech Stocks to Buy Hand Over Fist in October
These longtime leading biotech stocks still have plenty of upside ahead. 
Via The Motley Fool
Want to Invest in the Weight Loss Boom? Consider Buying These 2 Stocks
Investing in the most popular players in the space isn't the only valid approach. 
Via The Motley Fool
3 Magnificent Dividend Stocks to Buy in October
These dividend stocks are great picks as the fall season gets underway. 
Via The Motley Fool
Should You Buy the Dip on This Top Growth Stock?
The biotech needs to overcome an issue most drugmakers face at some point. 
Via The Motley Fool
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention. 
Via Investor's Business Daily
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Federal Judge Rules Amgen Must Face Tax Liability Lawsuit That Alleges Reckless Concealment Of $10.7B Tax Bill
Amgen faces a class-action lawsuit over allegations of concealing a $10.7 billion tax dispute with the IRS, with shareholders accusing the company of delaying critical disclosures. A federal judge... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
AskSlim Market Week - Friday, Sep. 27
An analysis and commentary on the financial markets. 
Via Talk Markets
Stock Market Rally Hits Fresh Highs, Fueled By Micron Earnings, China Stimulus: Weekly Review
The S&P 500 hit record highs, fueled by Micron and Chinese stimulus. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Taiwan Semiconductor, American Tower, Trane Technologies And A Health Care Stock On CNBC's 'Final Trades'
Analyst Stephen Weiss of Short Hills Capital Partners said he still finds Taiwan Semiconductor Manufacturing Company cheap. 
Via Benzinga
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
Amgen releases Phase 3 trial data for rocatinlimab and Uplizna, with analysts projecting strong sales despite competition in the atopic dermatitis and myasthenia gravis markets. Attention shifts to... 
Via Benzinga
Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases
Amgen tested its drug, Uplizna, in generalized myasthenia gravis, a market where Argenx's Vyvgart leads. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
47 48 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.